Cited by 119Lipid metabolism and disordersNuclear Structure and FunctionGenomics and Rare Diseases

The DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.

Köbberling Type of Familial Partial Lipodystrophy

Open access

Abstract

OBJECTIVE: The phenotypic expression of partial lipodystrophy is present in two familial syndromes: familial partial lipodystrophy type 1 (FPLD1), with fat loss from the extremities, and central obesity and FPLD type 2, with fat loss from the extremities, abdomen, and thorax. The latter disorder is associated with mutations in the LMNA gene. FPLD1 is thought to be rare. Here, we report 13 subjects with FPLD1, suggesting that this syndrome is more common than previously thought. RESEARCH DESIGN AND METHODS: Fasting glucose, plasma lipids, leptin, HbA(1c), and anthropomorphic measurements were evaluated in 13 subjects with clinical features of FPLD1 and are compared with two age-matched control groups, with and without diabetes. RESULTS: Only women with clinical features of FPLD1 have been identified. Although they lack extremity and gluteal subcutaneous fat, they do have truncal obesity. Skinfold thickness on the arm and leg was significantly less than that in control subjects. The ratio of skinfold thickness from abdomen to thigh was significantly higher in subjects, suggesting an easy method for identifying affected patients. FPLD1 subjects also had components of the metabolic syndrome, including hypertension, insulin resistance, and severe hypertriglyceridemia resulting in pancreatitis. Premature coronary artery disease was present in 31% of subjects. None of the subjects had coding mutations in the LMNA gene or in the gene coding for peroxisome proliferator-activated receptor (PPAR)-gamma. CONCLUSIONS: FPLD1 is more common than previously described, but the diagnosis is often missed. Early recognition and intensive treatment of hyperlipidemia and diabetes in FPLD1 is important for prevention of pancreatitis and early cardiovascular disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/diacare.26.6.1819

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Research works printed but not linked: 1

  1. Savage DB, Acerine C, Jebb S, Cinti S, Dixon A, Umpleby M, Vidal-Puig A, O’Rahilly S: Insight into the physiological effects of PPARg from humans with dominant negative mutations. In Proceedings of the First International Workshop on Lipoatrophic Diabetes. Bethesda, MD, Office of Rare Diseases, National Institutes of Health, 2001, p. 53

Cited by

Sorted by citations

See all 119

Metadata

Authors
Herbst, K. L., Tannock, L. R., Deeb, S. S., Purnell, J. Q., Brunzell, J. D., & Chait, A.
Affiliations
  • University of Washington (US)
  • Oregon Health & Science University (US)
Venue
Diabetes Care
Published
2003-06-01
Volume
26
Issue
6
Pages
1819-1824
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2086501247
Cited by
119
References
29
Citations by year
2026: 4 · 2025: 3 · 2024: 6 · 2023: 3 · 2022: 9 · 2021: 4 · 2020: 7 · 2019: 8 · 2018: 7 · 2017: 8 · 2016: 4 · 2015: 8 · 2014: 2 · 2013: 5 · 2012: 7
FWCI
2.20
Type
journal article
Language
en
Open access
Locations
  • Diabetes Care (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institute of Diabetes and Digestive and Kidney Diseases (P01-DK 17047, DK02689-04, T32-DK-07247, K23DK002689, P30DK017047, T32DK007247)
  • National Center for Research Resources (M01-RR 00037, M01RR000037)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Structure and Function
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
Keywords
LMNA gene, abdominal obesity, skinfold thickness, hypertriglyceridemia, pancreatitis, insulin resistance, metabolic syndrome, coronary artery disease, diabetes mellitus, PPARγ
MeSH terms
Anthropometry, Body Composition, Exons, Female, Humans, Lipodystrophy, Obesity, Skinfold Thickness, Syndrome, Transcription Factors, Washington, Receptors, Cytoplasmic and Nuclear, Leptin, Lamin Type A, White People

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review